NUTM2A (NUT Family Member 2A)

We suggest that HGESS with BCOR alterations may warrant reclassification as 'BCOR-altered uterine sarcomas'.

[This retracts the article DOI: 10.3892/ol.2021.13059.].

This study introduces a novel salivary and lung tumor entity driven by NFATC2::NUTM2A/B fusions and displaying myoepithelial-like morphology but imperfect myoepithelial immunophenotype. Report of more cases should shed light on the biological properties and appropriate therapeutic strategies of this novel neoplasm.

The clinical implications of these findings are significant, as NUTM2A-AS1 holds promise as a biomarker for cancer diagnosis and prognosis and as a target for novel therapeutic strategies. Future research should prioritize in vivo studies and clinical trials, leveraging emerging technologies such as CRISPR and single-cell RNA sequencing, to fully elucidate the therapeutic potential of targeting NUTM2A-AS1 in personalized cancer treatment.

Our study establishes a risk model that effectively predicts clinical outcomes and immune response in STAD.

A positive RNA-seq or methylation array analysis result may be sufficient evidence for a diagnosis of CIC-RS in the appropriate histologic context. A negative or inconclusive/unclassified RNA-seq or methylation array analysis result in a tumor with high initial suspicion for CIC-RS likely requires careful reevaluation.

Among this group, MGA::NUTM1-fusion sarcomas might represent a distinctive subset. NUTM1 IHC does not reliably detect NUTM2A/NUTM2G-rearranged sarcomas.

Furthermore, NUTM2A-AS1 expression in cisplatin-resistant NB cells was transactivated by NR1D1. In summary, our results unveil the molecular or biological relationship within the NR1D1/NUTM2A-AS1/B7-H3 axis in NB cells under cisplatin treatment, providing an intriguing avenue for fundamental research into cisplatin-resistant NB.

In addition, lncRNA NUTM2A-AS1 positively regulated of YAP1 expression in glioma cells. In conclusion, silencing of lncRNA NUTM2A-AS1 inhibited proliferation and induced apoptosis in human glioma cells via the miR-376a-3p/YAP1 axis.

We discovered a previously undescribed YWHAE::NUTM2E translocation in the tumor. Our patient's favorable outcome suggests that intensive multimodality therapy with curative intent is appropriate for young patients with high-grade endometrial stromal sarcoma and highlights the importance of fertility preservation.

NUTM2A-AS1 promotes cancer stem cell-like traits in PCa cells by targeting PRMT5 through miR-376a-3p. Therefore, these NUTM2A-AS1-based novel insights into tumour therapy hold promise for patients with PCa.

Our research proposed NUTM2A-AS1 as an oncogenic lncRNA that facilitates CRC malignancy by upregulating FAM3C expression, which might provide new insight and a promising therapeutic target for the diagnosis and treatment of CRC.